Biologics and the BPCIA: The Patent Dance, Biosimilar Approval, and Exclusivity

Document type: Article Practice area: Intellectual Property — Patents Jurisdiction: United States (federal) Last reviewed: 5 September 2026

When Congress created an abbreviated pathway for biologics in 2010, it had a working model available: Hatch-Waxman had governed small-molecule generics for twenty-six years, and everyone understood how it operated.

Congress did not copy it. The Biologics Price Competition and Innovation Act — the BPCIA, enacted as part of the Affordable Care Act — borrows the basic idea of an abbreviated application and an early patent resolution mechanism, and then differs in nearly every particular. There is no Orange Book. There is no automatic stay. There is no 30-month clock. There is, instead, an elaborate private exchange of confidential information between the applicant and the reference product sponsor, conducted on a schedule of days, that determines which patents get litigated and when.

The reasons for the difference are technical and commercial. Biologics are large, complex molecules produced in living systems. A biosimilar is not chemically identical to its reference product and cannot be shown to be; it is shown to be highly similar with no clinically meaningful differences. And the patent landscape is not a short list of composition and formulation patents but a thicket that can run to dozens of patents covering the molecule, the cell line, the culture media, the purification process, the formulation, the device, and the methods of use — many of which are manufacturing patents that were never listed anywhere because there is no place to list them.

Those facts drove the design, and understanding the design explains why biosimilar litigation looks nothing like ANDA litigation.

The pathway

A biologic is approved under a Biologics License Application pursuant to 42 U.S.C. § 262(a) — a full application with its own clinical program.

A biosimilar is approved under § 262(k) — the abbreviated pathway, commonly called a 351(k) application after the Public Health Service Act section number.

What a 351(k) applicant must show:

• The product is biosimilar to the reference product: highly similar notwithstanding minor differences in clinically inactive components, with no clinically meaningful differences in safety, purity, and potency.
• Analytical studies demonstrating high similarity.
• Animal studies including toxicity assessment.
• A clinical study or studies sufficient to demonstrate safety, purity, and potency in one or more conditions of use.
• The same mechanism of action, route of administration, dosage form, and strength — for the conditions of use sought.
• Manufacture in facilities meeting standards designed to assure continued safety, purity, and potency.

FDA may waive elements of the requirement, and the agency's guidance has moved substantially toward analytical comparability doing more of the work and comparative clinical efficacy studies doing less, where the analytical package is strong.

Interchangeability is a separate and higher designation under § 262(k)(4). An interchangeable product may be substituted at the pharmacy without the prescriber's intervention, subject to state pharmacy law. The applicant must show that the product can be expected to produce the same clinical result in any given patient and, for a product administered more than once, that the risk of alternating or switching is not greater than the risk of continued use of the reference product. Switching studies were long the practical requirement; the agency's approach has evolved as analytical methods have improved.

The commercial significance of interchangeability is large, because automatic substitution is what drives generic-style uptake. A biosimilar that is not interchangeable must be prescribed by name.

Exclusivity

Twelve years. Under § 262(k)(7), a 351(k) application may not be approved until twelve years after the date of first licensure of the reference product.

Four years. A 351(k) application may not even be submitted until four years after first licensure.

Why this is different from small molecules. The five-year NCE exclusivity for a new chemical entity is generous; twelve years is extraordinary. It reflects the compromise that produced the statute — a longer protected period in exchange for creating the pathway at all — and it means the patent questions frequently matter less than the exclusivity.

What does not restart the clock. A supplement, a new indication, a new route, a new dosage form, a change in strength, or a modification producing a structural change that does not result in a change in safety, purity, or potency. The exclusivity attaches to the first licensure of the reference product, and sponsors cannot reset it by reformulating.

Pediatric exclusivity adds six months, as with small molecules.

First interchangeable exclusivity. The first biosimilar determined to be interchangeable with a reference product receives a period during which FDA will not determine a subsequent product interchangeable with that reference product. The period is defined by reference to the earlier of specified events keyed to first commercial marketing and to litigation outcomes — a considerably more complex provision than the 180-day generic exclusivity, and one whose practical value has been debated.

The patent dance

Here is where the statute departs most sharply from Hatch-Waxman. There is no public patent list. Instead, § 262(l) establishes a private, staged exchange of confidential information on a schedule measured in days.

Step 1 — Disclosure (within 20 days of FDA accepting the application). The applicant provides the reference product sponsor with a copy of the 351(k) application and information describing the manufacturing process. This is remarkable: the applicant hands its competitor its regulatory dossier and its process, subject to confidentiality provisions in the statute.

Step 2 — Sponsor's list (within 60 days). The sponsor provides a list of patents it believes could reasonably be asserted, and identifies which it would be prepared to license.

Step 3 — Applicant's response (within 60 days). The applicant provides, for each listed patent, a detailed statement of the factual and legal basis for its opinion that the patent is invalid, unenforceable, or not infringed — or a statement that it does not intend to market before the patent expires. The applicant may also provide its own list of patents it believes the sponsor could assert.

Step 4 — Sponsor's reply (within 60 days). For each patent on the applicant's list and for each patent the applicant contends is invalid or not infringed, the sponsor provides a detailed statement of the factual and legal basis for its opinion that the patent will be infringed, and a response on validity and enforceability.

Step 5 — Negotiation (15 days, extendable). The parties negotiate to agree on which patents will be the subject of an immediate infringement action.

Step 6 — If they cannot agree. The applicant tells the sponsor how many patents it will list; the parties simultaneously exchange lists of the patents each wants litigated, with the number the applicant may list constrained by the number the sponsor lists. The immediate action covers the patents on the exchanged lists.

Step 7 — The immediate action (within 30 days of the exchange or agreement). The sponsor brings an infringement action on the agreed or exchanged patents.

Step 8 — Notice of commercial marketing (180 days before first commercial marketing). The applicant must give notice, and the sponsor may then seek a preliminary injunction on patents that were on either list but not in the first action.

What the dance accomplishes. It substitutes a private, information-rich negotiation for a public list. Both sides learn a great deal about the other's position before any complaint is filed, and the set of litigated patents is narrowed by agreement.

What it costs. The applicant discloses its application and its manufacturing process to its competitor. That is a genuine trade secret exposure, and it is the principal reason some applicants decline to dance at all.

Sandoz v. Amgen: is the dance mandatory?

The statute says the applicant "shall" provide its application. What happens if it does not?

Sandoz Inc. v. Amgen Inc., 582 U.S. 1 (2017) answered two questions and reshaped the practice.

The first holding: no federal injunction to compel the dance

Amgen argued that § 262(l)(2)(A)'s disclosure requirement was mandatory and enforceable by injunction. The Court disagreed, reasoning from the statute's own structure.

The statute supplies its own remedy. Section 262(l)(9)(C) provides that if the applicant fails to provide the application and manufacturing information, the sponsor — but not the applicant — may bring a declaratory judgment action on any patent that claims the biological product or a use of it. And 35 U.S.C. § 271(e)(2)(C)(ii) makes the failure to provide the application itself an act of artificial infringement, permitting the sponsor to sue immediately on any patent.

Because Congress specified consequences, those consequences are exclusive as a matter of federal law. An injunction compelling disclosure is not available under federal law.

The Court remanded the question whether an injunction might be available under state law — an unfair competition theory — leaving that to the Federal Circuit, which subsequently held such claims preempted.

The practical consequence: the dance is optional. An applicant may decline to disclose, accepting that the sponsor may then sue immediately on any patent it chooses, without the narrowing the dance produces.

The second holding: the 180-day notice may be given before approval

Amgen also argued that the 180-day notice of commercial marketing under § 262(l)(8)(A) could only be given after FDA licensure — which would have added 180 days to the twelve-year exclusivity in every case.

The Court held otherwise. The notice may be given before licensure. The provision requires notice 180 days before commercial marketing, not 180 days after approval.

This mattered enormously. Under Amgen's reading, every biosimilar entry would have been delayed by six months beyond the exclusivity period. The Court's reading means the notice can be given during review, and the 180 days can run concurrently with the tail of the review.

Not dancing

After Sandoz, an applicant chooses whether to participate.

Reasons to dance:

• Control the litigation scope. The dance narrows the patents in the first action to those the parties agree on or exchange, rather than everything the sponsor wants to assert.
• Information. The sponsor's detailed statements reveal its infringement and validity positions before any complaint.
• Sequencing. The first action is limited; the remaining patents come later, on a preliminary injunction posture where the sponsor bears the burden.
• Signal. A confident applicant that discloses its process is telling the sponsor something about its non-infringement position.

Reasons not to dance:

• Trade secret exposure. Handing your manufacturing process to your competitor is a real cost, and the statutory confidentiality provisions are narrower than a negotiated protective order.
• Speed. The dance takes months.
• The process is the patent risk. For a biosimilar, the manufacturing process is where much of the sponsor's patent estate lives, and disclosing the process is disclosing infringement analysis.
• The consequence is bounded. Not dancing lets the sponsor sue immediately on any patent — but it must still prove infringement without the applicant's process information, which it obtains only in discovery under a protective order.

What has happened in practice. Both approaches are used. Applicants with process advantages they wish to protect frequently decline; applicants seeking to narrow the litigation and accelerate resolution frequently participate. Partial participation — providing the application but resisting some later steps — has produced its own litigation.

No automatic stay, and why that changes everything

Hatch-Waxman gives the brand a 30-month stay for the price of filing suit. The BPCIA gives the sponsor nothing comparable.

What the sponsor gets instead:

• The immediate action under § 262(l)(6), which proceeds as ordinary patent litigation with no automatic delay of FDA approval.
• The right to seek a preliminary injunction after the 180-day notice, on patents that were listed but not in the first action.

Which means the sponsor must prove entitlement to an injunction: likelihood of success, irreparable harm, balance of equities, and the public interest — the ordinary standard, applied to a product the applicant has spent years developing and is about to launch.

Irreparable harm is the contested element. A sponsor argues price erosion, permanent loss of market share, and the impossibility of restoring a biologics market once a biosimilar enters. An applicant argues that money damages are calculable, that the sponsor's own licensing history shows it values the patent in dollars, and that delay harms patients and payers.

The 180-day notice is what makes the injunction practicable. Without it, the sponsor would learn of launch when it happened. With it, the sponsor has six months to prepare and file.

The practical effect. Biosimilar patent litigation is preliminary injunction litigation, compressed, on an incomplete record, with enormous stakes on both sides — and it is why so many of these disputes settle on an entry date before the motion is decided.

The patent thicket

An ANDA filer certifies to the patents in the Orange Book — typically a handful. A 351(k) applicant faces something different.

What the sponsor's estate typically contains:

• Composition patents on the molecule, often expired or expiring by the time exclusivity runs.
• Method-of-use patents for each approved indication and for later-discovered uses.
• Cell line and expression system patents.
• Culture media and process patents — feeding strategies, temperature shifts, harvest conditions.
• Purification patents — chromatography sequences, viral inactivation steps.
• Formulation patents — buffers, stabilizers, surfactants, concentrations.
• Device patents where the product is presented in an autoinjector or prefilled syringe.
• Analytical method patents.

The count can exceed one hundred for a major product. There is no Orange Book, so there is no list to work from — which is precisely what the dance's step 2 is for.

Why manufacturing patents dominate. For a small molecule, the compound patent is the fortress and the process is incidental. For a biologic, the molecule may be off patent while the practical means of making it at commercial scale and consistent quality remain protected. A biosimilar developer must design a process that produces a highly similar molecule without infringing — which is genuinely difficult and is the central technical challenge of the business.

The strategic consequence. Sponsors continue to file process and formulation patents throughout a product's life, and the effective exclusivity of a major biologic frequently extends well past the twelve-year statutory period. Whether this is legitimate incremental innovation or exclusivity extension is contested, and it is the subject of legislative proposals, FTC attention, and antitrust litigation.

Artificial infringement, biologics edition

35 U.S.C. § 271(e)(2)(C) supplies the jurisdictional hook, and it has two branches.

Branch (i) — it is an act of infringement to submit a 351(k) application with respect to any patent that is identified in the list described in § 262(l)(3)(A), that is, the sponsor's list, where the applicant has participated in the dance.

Branch (ii) — where the applicant fails to provide the application and manufacturing information under § 262(l)(2)(A), it is an act of infringement to submit the application with respect to any patent that could be identified under § 262(l)(3)(A).

The asymmetry is deliberate. An applicant that dances limits the universe of patents that can be immediately asserted to those on the sponsor's list. One that does not dance exposes itself to any patent the sponsor could have listed.

And § 271(e)(6) addresses the applicant that provides the application late or incompletely, with its own consequences for the timing of the sponsor's remedies.

Practical note. Because the infringement is artificial and the product has not been sold, the remedies mirror Hatch-Waxman: an order setting the approval date, injunctive relief, and damages only where there has been commercial manufacture, use, or sale. An at-risk launch is the one path to a damages case, and the exposure is the sponsor's lost profits on a product that may generate billions annually.

A worked sequence

Tessendorf Biologics markets Velcaris, a monoclonal antibody first licensed in 2014 for two autoimmune indications. Annual U.S. revenue: $3.4 billion. Its estate includes eleven unexpired patents: two on formulations, five on cell culture and purification processes, two on methods of use, and two on the autoinjector device.

Year 12 minus 18 months. Harlow Biosciences files a 351(k) application referencing Velcaris. FDA accepts it for review.

Day 20. Harlow elects to dance and provides its application and a description of its manufacturing process, subject to the statutory confidentiality provisions. Harlow's reasoning, documented internally: its purification process is genuinely different from Tessendorf's and it wants that established early; and it wants the litigation narrowed rather than facing eleven patents at once.

Day 80. Tessendorf lists nine patents — both formulations, four process patents, one method-of-use patent, and both device patents — and offers to license the device patents on terms.

Day 140. Harlow responds with detailed statements: it does not infringe the process patents because its purification sequence differs in specified respects; the formulation patents are invalid over prior art; it will not market the autoinjector presentation, mooting the device patents; and it is carving out the second indication, mooting the method-of-use patent. Harlow lists two additional patents it believes Tessendorf could assert.

Day 200. Tessendorf replies, contesting the non-infringement positions on two process patents and maintaining validity of the formulations.

Day 215. Negotiation. The parties agree that the first action will cover three patents: one formulation patent and two process patents. This is the narrowing the dance exists to produce.

Day 245. Tessendorf files the immediate action in the District of Delaware on the three agreed patents.

Months 8–26. Ordinary patent litigation. No stay. FDA's review proceeds in parallel and is not affected. The central factual dispute is what Harlow's purification process actually does, which Tessendorf explores through the process information provided under the dance and through discovery.

Month 22. Harlow gives its 180-day notice of commercial marketing, which under Sandoz it may do before licensure. The clock runs concurrently with the last months of FDA review.

Month 23. Tessendorf moves for a preliminary injunction on the two patents that were listed but not in the first action.

The injunction fight. Tessendorf argues irreparable harm from permanent price erosion and market share loss in a market where the first biosimilar entrant sets the reference price. Harlow argues the harm is quantifiable, that Tessendorf's own licensing history prices these patents, and that the public interest favors entry.

Month 26. The court denies the preliminary injunction on likelihood of success — Harlow's non-infringement position on the process patent is substantial — and the parties settle three weeks later on an entry date six months out, with a royalty-bearing license and acceleration if another biosimilar enters.

Month 32. Harlow launches, as a biosimilar but not interchangeable. Uptake is slower than a generic launch because substitution requires a prescriber decision. Tessendorf's revenue declines by roughly 25 percent in the first year rather than the 80 percent a small-molecule generic entry would produce.

Three observations.

The dance did what it was designed to do. Eleven patents became three in the first action, and two more in the injunction motion. Without it, Harlow would have faced all eleven at once.

The absence of a stay changed the leverage. Tessendorf had to prove entitlement to an injunction rather than receiving thirty months for the price of a filing fee, and when it could not, it settled quickly.

Interchangeability was the commercial variable that mattered most. Harlow's decision not to pursue it initially — to reach the market faster — cost it far more in uptake than the litigation cost either side.

Confidentiality under the statute

The dance requires an applicant to hand its competitor a regulatory dossier and a manufacturing description. Section 262(l)(1) supplies the protection, and practitioners should understand exactly what it does.

Who may receive the information. Outside counsel for the sponsor who does not engage in patent prosecution relating to the reference product, and one in-house representative who likewise does not engage in such prosecution. That is the statutory default.

What it may be used for. Solely for determining whether a claim of patent infringement could reasonably be asserted, and for the resulting litigation.

What it forecloses. Use for any other purpose, including business, competitive, and regulatory purposes.

Where the statutory protection is thinner than a negotiated order:

• The class of permitted recipients is narrow, but the statute does not set out designation tiers, clawback procedures, or the mechanics of sealed filing.
• Enforcement runs through breach of the statute rather than through a court's contempt power over a protective order.
• The prosecution bar is defined by the statute's terms rather than by a negotiated scope and duration.

The practical response. Parties routinely negotiate a supplemental confidentiality agreement layering ordinary protective-order machinery on top of the statutory floor — designation tiers, a broader and longer prosecution bar, filing procedures, and a return-or-destroy obligation. An applicant should propose it with the disclosure, not after.

And an applicant's internal discipline matters. The manufacturing description should be prepared by counsel with the technical team, disclosing what the statute requires and not more. Over-disclosure cannot be recalled.

Why so few of these cases reach judgment

Most BPCIA disputes settle, and the structural reasons are worth stating.

The exclusivity usually decides the date. Twelve years plus pediatric exclusivity is a long time, and by the time a biosimilar can be approved, several of the sponsor's patents have expired. The remaining dispute is often about a handful of process patents and a period of months.

The sponsor's leverage is weaker than in Hatch-Waxman. No automatic stay means the sponsor must win a preliminary injunction to delay entry, on the ordinary four-factor standard, against a well-funded applicant with a substantial non-infringement position.

The applicant's exposure is enormous. A launch at risk against a $3 billion product exposes the applicant to the sponsor's lost profits, which can exceed the applicant's entire enterprise value.

Both sides face asymmetric ruin. The sponsor risks losing a franchise; the applicant risks a company-ending judgment. That is the classic setting for a negotiated date.

And the deals look like Hatch-Waxman deals. An entry date, a royalty-bearing license, acceleration triggers, most-favored-entry provisions, and — because value flowing from the sponsor to the applicant raises the same questions — an antitrust analysis under the framework of FTC v. Actavis, Inc., 570 U.S. 136 (2013). The reporting obligation applies to biosimilar settlements as it does to generic ones.

Where the framework is under pressure

Patent thickets. Legislative proposals would limit the number of patents a sponsor may assert in a biosimilar action or require earlier identification. The FTC has expressed concern about thickets and about Orange Book listing practices in the adjacent small-molecule context.

Interchangeability. FDA's evolving approach — reducing reliance on switching studies where the analytical package supports it — would, if fully implemented, make interchangeability more attainable and substantially increase biosimilar uptake. Legislative proposals to eliminate the separate designation entirely have been introduced.

Exclusivity length. Proposals to reduce the twelve-year period recur, with the usual sectoral divide.

Product hopping and device changes. Transitioning a market to a new presentation — a different device, a higher concentration, a subcutaneous version of an intravenous product — before biosimilar entry has drawn antitrust attention, as it has for small molecules.

Rebate walls and contracting. Payer contracting practices that condition rebates on formulary exclusion of biosimilars have been the subject of private antitrust litigation and agency interest. This is increasingly where the commercial fight happens, rather than in the patent case.

The practical point for counsel. A biosimilar strategy is a patent strategy, a regulatory strategy, and a market access strategy, and the third has become as consequential as the first two. A client planning entry needs all three assessed together.

BPCIA versus Hatch-Waxman, side by side

The three rows that matter most are the absence of a stay, the twelve-year exclusivity, and the substitution difference. Together they explain why biosimilar litigation is preliminary injunction practice, why the patent fight often matters less than the exclusivity, and why market uptake is slower than anyone predicted when the statute passed.

Frequently asked questions

Is the patent dance mandatory? No. Sandoz Inc. v. Amgen Inc., 582 U.S. 1 (2017) held that federal law provides no injunction to compel disclosure. The statute's own consequences — immediate suit on any patent the sponsor could have listed, under 35 U.S.C. § 271(e)(2)(C)(ii) — are the remedy.

Can the 180-day notice be given before FDA approval? Yes. That is the second holding of Sandoz, and it prevents the notice from adding six months to the twelve-year exclusivity.

Is there a 30-month stay? No. The sponsor must obtain a preliminary injunction on the ordinary four-factor standard.

What is the difference between biosimilar and interchangeable? A biosimilar is highly similar with no clinically meaningful differences. An interchangeable product additionally may be substituted at the pharmacy without prescriber intervention, subject to state law. The commercial difference is large.

How long is the exclusivity? Twelve years from first licensure of the reference product before a 351(k) application may be approved; four years before one may be submitted. Pediatric exclusivity adds six months.

Does a new indication restart the twelve years? No. The clock runs from first licensure of the reference product, and supplements, new indications, new routes, and new dosage forms do not restart it.

Why do biosimilars face so many patents? Because there is no Orange Book and because the sponsor's estate includes cell line, culture, purification, formulation, device, and analytical patents. The molecule may be off patent while the practical means of making it are not.

What is the applicant's biggest risk? An at-risk launch. Damages are the sponsor's lost profits on a product that may generate billions annually, which can exceed the applicant's enterprise value.

Do these cases go to trial? Rarely. The combination of a short remaining exclusivity window, weak sponsor leverage without a stay, and catastrophic applicant exposure produces settlements on an entry date.

Are those settlements reviewed? Yes. They are reportable to the FTC and DOJ and analyzed under FTC v. Actavis like generic settlements.

The uptake problem

The statute has been in force long enough to assess, and the assessment is mixed in a way that surprises people who expected generic-style price collapse.

What was expected. Biosimilars would enter after twelve years, prices would fall by seventy or eighty percent, and the savings would be enormous.

What happened. Entry has been slower than projected, and where biosimilars have entered, uptake and price erosion have varied enormously by product and by therapeutic area. Some markets have seen rapid conversion and substantial discounting; others have seen a biosimilar launch and capture single-digit share for years.

The reasons are structural rather than legal:

Substitution requires interchangeability. Without it, every switch requires a prescriber decision, and prescribers switching a stable patient on a biologic face a clinical judgment that pharmacists substituting a small molecule do not.

Development cost is high. A biosimilar program costs a substantial fraction of an original program — analytical characterization, comparative clinical work, and a manufacturing plant. That limits the number of entrants and keeps prices above generic levels.

Rebate contracting. Reference product sponsors can offer payers rebates conditioned on formulary position across a portfolio, and a biosimilar offering a lower list price may still be more expensive to the payer net of rebates. This is the practice that has drawn antitrust attention.

Device and presentation differentiation. Transitioning patients to a new autoinjector, a higher concentration, or a subcutaneous formulation before biosimilar entry moves the market to a product the biosimilar does not reference.

Physician and patient familiarity. Biologics are frequently administered in a clinical setting with training, support programs, and long-term patient relationships that a new entrant must replicate.

Why this matters to counsel. A client evaluating a biosimilar program is making a commercial bet in which the patent litigation is one input among several, and frequently not the largest. The questions that determine the outcome — interchangeability, payer contracting, device strategy, and site-of-care economics — are not patent questions, and a legal team that addresses only the patents has answered a fraction of the problem.

What this means strategically

For a reference product sponsor:

Build the process estate continuously. The composition patent will expire. The patents that determine effective exclusivity are the ones covering how the product is actually made at commercial scale — cell lines, media, feeding strategies, purification sequences, and formulation. File them throughout the product's life.

Prepare the list before you need it. The dance gives sixty days to produce a list of patents that could reasonably be asserted. For a product with a hundred-patent estate, that analysis should exist in draft before any 351(k) application is filed.

Decide the licensing posture deliberately. Step 2 requires identifying which listed patents you would license. Offering a license on the device patents while holding the process patents is a signal, and it narrows the fight to where you are strongest.

Plan the injunction case early. Without a stay, the preliminary injunction is the only delay mechanism, and irreparable harm evidence — price erosion modeling, market share analysis, the irreversibility of formulary displacement — takes months to develop. Start it when the application is accepted, not when the notice arrives.

And do not neglect market access. Rebate contracting, formulary placement, and device differentiation frequently protect more revenue than the patents do, and each carries its own antitrust analysis.

For a biosimilar developer:

Design the process around the estate. This is the central technical program, and it should be informed by patent analysis from the first bioreactor run. Document the design-around contemporaneously.

Decide about the dance with the trade secret exposure quantified. The manufacturing description goes to your competitor. Prepare it with counsel, disclose what the statute requires, and negotiate a supplemental confidentiality agreement layered on the statutory floor.

Take interchangeability seriously. The uptake difference is large, and the additional development cost is frequently less than the revenue difference in the first two years. Model both paths before choosing.

Give the 180-day notice as early as Sandoz permits. Running it concurrently with the tail of FDA review is worth six months of revenue.

And model the at-risk launch honestly. The exposure is the sponsor's lost profits, not yours. For a large product this can exceed the value of the company, which is why the analysis belongs at board level with written appellate assessment.

The short version

The BPCIA borrows Hatch-Waxman's idea and changes almost every mechanism.

Twelve years of reference product exclusivity — four before an application may even be submitted — and it does not restart for new indications or presentations.

There is no Orange Book. The patent dance of 42 U.S.C. § 262(l) substitutes a private, staged exchange in which the applicant discloses its application and manufacturing process and the parties negotiate which patents get litigated first.

The dance is optional after Sandoz Inc. v. Amgen Inc., 582 U.S. 1 (2017), and the price of declining is that the sponsor may sue immediately on any patent it could have listed.

The 180-day notice may be given before licensure, which prevents it from adding six months to the exclusivity.

There is no automatic stay. The sponsor's delay mechanism is a preliminary injunction on the ordinary four-factor standard, which is a far weaker position than the thirty months Hatch-Waxman supplies for a filing fee.

The patents are process patents. The molecule may be off patent while the practical means of manufacturing it are not, and the estate can run to dozens.

Substitution requires interchangeability, which is a separate and higher designation and is the single largest commercial variable.

Damages arise only on an at-risk launch, and the measure is the sponsor's lost profits — which for a major biologic can exceed the applicant's enterprise value.

And most of these disputes settle on an entry date, for the same reason most Hatch-Waxman cases do: both sides face asymmetric ruin, the remaining exclusivity window is short, and a negotiated date is worth more to each than the outcome of a motion.

Related documents

• Navigating the BPCIA Patent Dance: A Practical Guide
• BPCIA Patent Exchange Checklist: A Practical Checklist
• Biosimilar Litigation Toolkit: Disclosure Lists and Preliminary Injunction Briefing
• Hatch-Waxman Litigation: The Orange Book, Paragraph IV Certifications, and the 30-Month Stay
• Running an ANDA Litigation: A Practical Guide
• Patent Eligibility Under Section 101: The Alice/Mayo Framework and How Courts Apply It
• Preliminary Injunctions and Temporary Restraining Orders: Emergency Relief in Federal Court

This article is general information, not legal advice, and does not create an attorney-client relationship.